anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a monoclonal antibody targeting a coronavirus S protein NTD region and application thereof, wherein the amino acid sequences of a heavy chain variable region CDR1, a CDR2 and a CDR3 of the monoclonal antibody are respectively shown as SEQ ID NO. 2, SEQ ID NO. 3 and SEQ ID NO. 4, and the amino acid sequences of a light chain variable region CDR1, a CDR2 and a CDR3 are respectively shown as SEQ ID NO. 10, SEQ ID NO. 11 and SEQ ID NO. 12, and the monoclonal antibody has good binding activity to the coronavirus S protein NTD domain and can be used for early screening and diagnosis of diseases related to coronavirus infection.
Hypertrophic cardiomyopathy (HCM), defined clinically by the presence of unexplained left ventricular hypertrophy (LVH), with wall thickness ≥ 1.5 cm, is a phenotype in search of a diagnosis, which is most often a genetically determined, cardiac exclusive, or systemic disorder. Familial evaluation and genetic testing are required for definitive diagnosis. The role of genetic findings in predicting development of disease, outcomes, and increasingly to guide management is evolving with access to larger data sets. The specific mutation and sex of the patient are important determinants that ultimately are likely to guide management. The genetic/familial evaluation is influenced by the accuracy of the clinical diagnosis and the extent/expertise of the genetic laboratory. Genetic testing in a patient with unexplained LVH without systemic manifestations will yield a definite/likely pathogenetic mutation in a sarcomere (30%-50%), regulatory/functional (10%-15%) or metabolic/syndromic (< 5%) gene associated with Mendelian inheritance. The importance of oligo- and polygenic determinants, usually in the absence of Mendelian inheritance, is under investigation with important implications, particularly related to familial evaluation and definition of risk of disease development in relatives of probands. The results of genetic testing are increasingly important in management strategies related to the use of the implantable cardioverter defibrillator for prevention of sudden death, use of myosin inhibitors for refractory symptoms in patients with and without outflow tract obstruction, and-on the immediate horizon-gene therapy. This review will focus on genetic and outcome data in sarcomeric HCM, and minor causative genes with robust evidence of their association will also be considered.
A training device for improving insomnia is provided, comprising a virtual reality unit and a control unit. The virtual reality unit comprises two earphones and an eye cover connected to the earphones. When the control unit executes the daytime relaxaion-assisted program, the control unit controls the earphones to play a daytime binaural beats with frequency following response. The daytime binaural beats with frequency following response have a first main carrier frequency tone and a first loading frequency tone differing from the first main carrier frequency tone by a first difference frequency rate. When the control unit executes the nighttime anti-insomnia-assisted program, the control unit controls the earphones to play the nighttime difference frequency tone. The nighttime difference frequency tone have a second main carrier frequency tone and a second loading frequency tone differing from the second main carrier frequency tone by a second difference frequency rate.
The invention provides a medicament for treating arthralgia due to wind-cold-dampness, prepared from the following medicinal materials in parts by weight: 150-200 parts of prepared aconite root, 80-120 parts of dried ginger, 180-220 parts of fineleaf schizonepeta herb, 90-110 parts of Chinese atractylodes, 85-105 parts of pubescent angelica root, 80-120 parts of notopterygium root, 85-110 parts of nutgrass galingale rhizome and 190-230 parts of garden balsam stem. The medicament is prepared by the following steps of: weighing the required amounts of medicinal materials, respectively pulverizing to 25-35 meshes, mixing uniformly and boxing, laminating a film on the box, and attaching sticking strips to the periphery of the box. When in use, a packing box is opened, the film on the box is stripped off, the medicinal powder in the box is mixed with warm water of 35-45 DEG C into a paste, the paste with the box is pasted onto an affected part, and the sticking strip is stuck to the skin; a patient stops moving as much as possible, and the medicament can be stripped off after 40-50 minutes. When few patients have skin redness and itching irritation reactions locally during using the product, the symptoms can be spontaneously relieved after the patients stop using the medicament, but the medicament is forbidden to be applied to damaged skin. The packing amount of the medicament is 40g of powder/box, and the effective period is 24 months. The packing box of the medicament is made of a disposable low-carbon material or an environment-friendly material.
PROBLEM TO BE SOLVED: To obtain a composition with slight side effects, and useful as e.g. a tonic medicine exhibiting significant efficacy in health maintenance/promotion and the treatment/prevention of diseases, an agent for sensitivity-related diseases, by including a processed product of a plant belonging to the genus Pfaffia and a flavonoid. SOLUTION: This composition is obtained by including (A) 21 processed product of a plant belonging to the genus Pfaffia such as Pfaffia glomerata and (B) a flavonoid such as vitamin P (e.g. enzyme-treated hesperidin, enzyme- treated rutin) in a weight ratio B to A of 0.001-1 on a solid basis; wherein the component A is e. g. a water extract derived from the roots of the above- mentioned plant. This composition is also useful as an immunopotentiator, antiallergic agent, neurotropic agent and/or tonic agent. Preferable usage and dose of this composition are as follows: about 1 mg to 1 g singly, one to four times a day or one to five times a week, for a period of one day to one year, orally administered, or parenterally administered (intracutaneously, subcutaneously, intramuscularly, or intravenously), per adult, in terms of the total amount of the components A and B on a solid basis.
The signs and symptoms of overdosage are those of hyperthyroidism [see Warnings and Precautions (5.4)and Adverse Reactions (6)] . In addition, confusion and disorientation may occur. Cerebral embolism, seizure, shock, coma, and death have been reported. Symptoms may not necessarily be evident or may not appear until several days after ingestion. 

Reduce the liothyronine sodium tablets dose or temporarily discontinued if signs or symptoms of overdosage occur. Initiate appropriate supportive treatment as dictated by the patient's medical status.

For current information on the management of poisoning or overdosage, contact the National Poison Control Center at 1-800-222-1222 or www.poison.org.
OBJECTIVES: Non-invasive ventilation use is increasing in patients from acute respiratory failure. However, nutritional assessment and medical nutritional therapy are often missed and patients may be frequently underfed. This review evaluates the tools for nutritional screening and assessment, assesses the use of medical nutritional therapy in various techniques of non invasive ventilation and suggested tools to improve this therapy.
METHODS, RESULTS: A review of the literature was performed to evaluate the tools available to define malnutrition and determine the energy needs of patients requiring non invasive ventilation. Energy and protein intake was assessed in 16 recent papers. High Flow Nasal Cannula Oxygen therapy and non invasive ventilation using mask were described and nutritional therapy determined in each condition.
UNLABELLED: The Global Leadership International Malnutrition Assessment seems to be the best assessment to be recommended. Energy expenditure is optimally obtained by indirect calorimetry. Patients with Non invasive ventilation are even more underfed than patients receiving High Flow Nasal Cannula Oxygen therapy.
CONCLUSIONS: A better determination of malnutrition, a more adequate energy requirement and an improved energy and protein administration are required in patients with acute respiratory failure treated with non invasive ventilation.
Patients submitted to motor rehabilitation program aimed at learning unimanual and bimanual coordinated sequences, along with personalized exercise according to tumor location (frontal vs parietal). For 6 months each patient will perform the motor training program in outpatient training session, checked by a physiotherapist for corrected execution at home 3 times/week, and is assessed for the correct training execution and progresses in training sessions each month, by physical therapists at the Rehabilitation Unit and on a weekly schedule by on-line distant monitoring (telemedicine).
Patients will be randomized 1:1 to the control group and the treatment group. The treatment group will receive 6 times of MG4101(allogeneic natural killer cells) on week 0, 1, 2, 5, 6, 7.
Participants will received an 8-week intervention consisting of exercise and pain neuroscience education. Pain neuroscience education will be conducted in line with international guidelines and will address the following topics: pain neurophysiology, nociception and nociceptive pathways, inhibition and spinal cord stimulation, peripheral and central sensitization, nervous system plasticity and the impact of variables such as stress, anxiety, sleep and exercise on pain behavior. Exercise will be performed in accordance with international guidelines for chronic NP. Motor control, endurance and strengthening exercises will be performed for the neck and scapulo-thoracic region.
PURPOSE: A cosmetic composition containing seaweed extract is provided to protect skin from ultraviolet and irritative and harmful environment. CONSTITUTION: A cosmetic composition comprises seaweed extract. The seaweed extract contains 3-100 weight parts of Undaria Pinatifida Sporophyll extract. The cosmetic composition further comprises UV protector and moisturizer. A method for manufacturing the cosmetic composition comprises: a step of dipping seaweed to the water; and a step of extracting at 100-65°C for 3-30 hours. The cosmetic composition suppresses skin aging and maintains health skin.
The presence of tertiary lymphoid structures (TLSs) on pancreatic pathological images is an important prognostic indicator of pancreatic tumors. Therefore, TLSs detection on pancreatic pathological images plays a crucial role in diagnosis and treatment for patients with pancreatic tumors. However, fully supervised detection algorithms based on deep learning usually require a large number of manual annotations, which is time-consuming and labor-intensive. In this paper, we aim to detect the TLSs in a manner of few-shot learning by proposing a weakly supervised segmentation network. We firstly obtain the lymphocyte density maps by combining a pretrained model for nuclei segmentation and a domain adversarial network for lymphocyte nuclei recognition. Then, we establish a cross-scale attention guidance mechanism by jointly learning the coarse-scale features from the original histopathology images and fine-scale features from our designed lymphocyte density attention. A noise-sensitive constraint is introduced by an embedding signed distance function loss in the training procedure to reduce tiny prediction errors. Experimental results on two collected datasets demonstrate that our proposed method significantly outperforms the state-of-the-art segmentation-based algorithms in terms of TLSs detection accuracy. Additionally, we apply our method to study the congruent relationship between the density of TLSs and peripancreatic vascular invasion and obtain some clinically statistical results.
The use of continuous positive airway pressure (CPAP) with a nasal mask during sleep is the gold standard treatment for moderate to severe obstructive sleep apnea (OSA). However, low adherence to CPAP is the main limiting factor in clinical practice. Recent studies suggest that unintentional air leak through the mouth contributes significantly to poor adherence to CPAP. Orofacial myofunctional therapy (OMT) is effective for treating mild to moderate OSA and has not been tested in patients with mouth air leaks. OSA patients using nasal CPAP and mouth air leaks will be recruited and will use the standard CPAP model and nasal mask during the first and last week of the study to record adherence and home leak. Patients will be treated by performing daily (3 times a day) orofacial myofunctional exercises aimed at strengthening the muscles of the oral cavity. Exercises will be supervised weekly for 3 months. All patients will undergo at the beginning and end of treatment: polysomnography with CPAP and nasal mask, speech-language pathology assessment adequated for OSA (scores ranging from 0 to 241, with higher values indicating greater dysfunction), quality of life questionnaire, and nasosinusal symptoms (SNOT -22), sleep quality (Pittsburgh) and sleepiness (Epworth). Polysomnography will include a pneumotachograph (Hans Rudolph) in the CPAP circuit to record flow and a magnetic jaw movement sensor (Brizzy) to record the episodes of mouth opening. The mouth air leak episodes were considered when they exceeded 20% above baseline (intentional leak with the mask fitted and mouth closed at the beginning of the PSG examination with CPAP) for a minimum of 10 seconds. Leaks ending with arousal or full awakening were considered arousal or full awakening associated with mouth air leak. Mouth opening during the leak episodes was determined by the difference between the amplitude at the end of the leak and the amplitude during the leak. Our hypothesis is that the orofacial myofunctional therapy will reduce mouth leakage in OSA patients treated with CPAP and nasal mask.
Eligible hemodialysis patients who are currently receiving an erythropoiesis stimulating agent (ESA) who enrol and sign consent will be randomized on a 1:1 basis to either remain on epoetin alfa or switch to darbepoetin alfa as their anemia therapy. Patients will be dosed with the assigned drug using a study algorithm to maintain their hemoglobin (Hb) level within the currently recommended range (100-120 g/L). There will be an initial "run in" period of a minimum of six weeks to ensure the patient's hemoglobin is stable within the target range. The trial itself will run for a subsequent twelve months (active phase). Every effort will be made to ensure that Hb stays within the target range during the study period. The primary outcome will be the total cost of each ESA therapy over the twelve month active phase. Data including Hgb, iron indices and dosing, and clinical events will be obtained from electronic sources and from the attending physicians and/or the clinical pharmacist.
FIELD: medicine, pediatrics, infectious diseases. SUBSTANCE: invention can be used in treatment of infectious diseases in children. Method involves administration of agents effecting on the level of obligate microorganisms and correcting deficiency of serum calcium. As such agent method involves using a preparation representing a powder a mixture of lyophilized bacterial mass of live bifidobacteria adsorbed on activated carbon particles and calcium gluconate and placed into a sealed bag containing 5 x 10 7  CFU, not less, of bifidobacteria immobilized on sorbent, 0.5-1 g of calcium gluconate, and 0.10-0.12 g of lactose. The preparation is dosed by one bag 1-3 times per a day, 30 min before eating for 10-14 days. Method provides reducing time for treatment of acute intestine infections, to recover disturbances of intestine microflora and metabolism and avoid adverse responses. EFFECT: enhanced effectiveness of treatment. 2 ex
The study in a 1:1 randomization ratio (36 subjects to experimental group). The treatment group received Herteppa Ethanolamine tablets and platelet transfusion.
BIAsp30 plus Metformin plus Placebo-Repaglinide. Double-Masked and randomized. Duration: 12 months.
BREO ELLIPTA, like other drugs containing beta2-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, and also cardiac arrhythmias, such as supraventricular tachycardia and extrasystoles [see Adverse Reactions (6.3)]. If such effects occur, BREO ELLIPTA may need to be discontinued. In addition, beta-agonists have been reported to produce electrocardiographic changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression, although the clinical significance of these findings is unknown [see Clinical Pharmacology (12.2)]. Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs.

In healthy subjects, large doses of inhaled fluticasone furoate/vilanterol (4 times the recommended dose of vilanterol, representing a 12- or 10-fold higher systemic exposure than seen in patients with COPD or asthma, respectively) have been associated with clinically significant prolongation of the QTc interval, which has the potential for producing ventricular arrhythmias. Therefore, BREO ELLIPTA, like other sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.

In a mortality trial with a median treatment duration of 1.5 years in 16,568 patients with moderate COPD and cardiovascular disease, the annualized incidence rate of adjudicated cardiovascular events (composite of myocardial infarction, stroke, unstable angina, transient ischemic attack, or on-treatment death due to cardiovascular events) was 2.5 per 100 patient-years for BREO ELLIPTA 100/25 mcg, 2.7 for placebo, 2.4 for fluticasone furoate 100 mcg, and 2.6 for vilanterol 25 mcg. Adjudicated, on-treatment deaths due to cardiovascular events occurred in 82 patients receiving BREO ELLIPTA 100/25 mcg, 86 patients receiving placebo, 80 patients receiving fluticasone furoate 100 mcg, and 90 patients receiving vilanterol 25 mcg (annualized incidence rate ranged from 1.2 to 1.3 per 100 patient-years for the treatment groups).
The present invention relates to the preparation of compositions comprising benzoyl peroxide, with or without other additional active ingredients. The process involves introducing benzoyl peroxide, along with any other active ingredients present, into a fatty substance that contains and protects the ingredients that would otherwise be unstable when in contact with one another. The composition is designed to allow all ingredients to become available for skin contact or skin absorption when the fatty substance softens and/or melts as the composition is applied to the skin. The benzoyl peroxide may be pre-micronized to a particle distribution size of about d 90  of 0.1 to 150 microns, preferably d 90  of 10 to 15 microns. Further, pharmaceutical or cosmetic ingredients may be contained within the fatty substances, with or without, benzoyl peroxide therein or may be present outside of the fatty substance but elsewhere within formulated pharmaceutical or cosmetic products using the active ingredients protected by the fatty substance. These compositions are useful in aqueous-based formulations to treat diseases by topical, transdermal and/or subcutaneous administration.
PURPOSE:A composition, obtained by blending a composition for the oral cavity containing a tranexamic acid as an active ingredient and an aldehyde perfume with a specific cyclic ketone, capable of improving bitter and sharp tastes and having excellent feeling of use without coloring even after preserving for a long period. CONSTITUTION:A composition for the oral cavity obtained by blending a composition for the oral cavity containing a tranexamic acid and/or salt thereof as an active ingredient and an aldehyde perfume, e.g. citral, trans-2-hexenal, etc., with one or two or more cyclic ketones selected from menthone, isomenthone and pulegone in an amount of 0.0001-1wt% based on the total composition. The composition is used for dentifrice, e.g. toothpaste, etc., mouthwash, dentine massage cream, etc., by adding a polishing agent, adhesive, sweetener, etc. EFFECT:Bitter and sharp tastes caused by the tranexamic acid can be suppressed by blending the cyclic ketone and discoloration by blending of the aldehyde perfume can be prevented to improve the preservation stability of the composition.
Hepatocellular carcinoma (HCC) is characterized by high incidence, high death rate and poor long term prognosis. Abnormal expression of circular RNA (circRNA) has been demonstrated to be closely associated with malignant progression of HCC. However, the effect of circZNF720 on HCC is largely incompletely understood. This study sought to explore the effect of circZNF720 on the progression of HCC by CCK-8, transwell, and flow cytometry experiments. The prognosis of circZNF720 on patients was analyzed by Kaplan-Meier curve. Then, the regulatory mechanisms among circZNF720, miR-421, and MAPK9 were identified by qRT-PCR, dual-luciferase reporter assay, and RIP analysis, respectively. The outcomes of this study disclosed that circZNF720 was lowly expressed in HCC, and this low expression was strongly linked with a poor prognosis for HCC patients. Overexpression of circZNF720 inhibited the proliferation, migration, and invasion of cells, and increased the apoptosis of cells. Mechanistic studies revealed that circZNF720 targeted miR-421 and regulated the development of HCC by acting as a sponge for miRNAs. In addition, MAPK9 was a downstream target of miR-421, and circZNF720 introduction hampered HCC progression by upregulating MAPK9 expression through sponging miR-421. In conclusion, circZNF720 restrained HCC progression by targeting miR-421/MAPK9. This study provides a novel target for the treatment of HCC.
BACKGROUND: Myotonic dystrophy type 1 (DM1) is a multiorgan disorder with significant cardiac involvement. ECG abnormalities, including arrhythmias, occur in 80 % of DM1 patients and are the second-most common cause of death after respiratory complications; however, the mechanisms underlying the arrhythmogenesis remain unclear. The objective of this study was to investigate the basis of the electrophysiological abnormalities in DM1 using the DMSXL mouse model.
METHODS: ECG parameters were evaluated at baseline and post flecainide challenge. Calcium transient and action potential parameters were evaluated in Langendorff-perfused hearts using fluorescence optical mapping. Calcium transient/sparks were evaluated in ventricular myocytes via confocal microscopy. Protein and mRNA levels for calcium handling proteins were evaluated using western blot and RT-qPCR, respectively.
RESULTS: DMSXL mice showed arrhythmic events on ECG including premature ventricular contractions and sinus block. DMSXL mice showed increased calcium transient time to peak without any change to voltage parameters. Calcium alternans and both sustained and non-sustained ventricular tachyarrhythmias were readily inducible in DMSXL mice. The confocal experiments also showed calcium transient alternans and increased frequency of calcium sparks in DMSXL cardiomyocytes. These calcium abnormalities were correlated with increased RyR2 phosphorylation without changes to the other calcium handling proteins.
CONCLUSIONS: The DMSXL mouse model of DM1 exhibited enhanced arrhythmogenicity associated with abnormal intracellular calcium handling due to hyperphosphorylation of RyR2, pointing to RyR2 as a potential new therapeutic target in DM1 treatment.